Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 3/20 | 0.45 |
| ▸ | CASP3 | P42574 | 3/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18452864 | 1.00 | TLR2 (0.45) | TLR2CASP3MDM4TP53PTPN1 | |
| SCHEMBL26262664 | 1.00 | TLR2 (0.45) | TLR2CASP3MDM4TP53PTPN1 | |
| SCHEMBL30919311 | 0.96 | PTPN1 (0.46) | TLR2PTPN1 | |
| SCHEMBL29938622 | 0.93 | PTPN1 (0.49) | TLR2CASP3PTPN1 | |
| SCHEMBL18452568 | 0.93 | PTPN1 (0.49) | TLR2CASP3PTPN1 | |
| SCHEMBL30919318 | 0.93 | PTPN1 (0.46) | TLR2PTPN1 | |
| SCHEMBL30948796 | 0.91 | CASP3 (0.46) | TLR2CASP3MDM4TP53KMT2A | |
| SCHEMBL26940363 | 0.91 | CASP3 (0.46) | TLR2CASP3MDM4TP53KMT2A | |
| SCHEMBL3044166 | 0.89 | TLR2 (0.46) | TLR2CASP3MDM4TP53KMT2A | |
| SCHEMBL30948677 | 0.89 | TLR2 (0.46) | TLR2CASP3MDM4TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-25 | — | — | US | disclosed |
| WO-2023202651-A1 | POLYMORPHIC FORMS OF GLUTAMINE ANTAGONIST AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-10-26 | — | — | WO | disclosed |
| US-11760723-B2 | Method of preparing a DON prodrug from L-pyroglutamic acid | DRACEN PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220194898-A1 | METHOD OF PREPARING A DON PRODRUG FROM L-PYROGLUTAMIC ACID | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | GLUL, GLS, GLS2 | TLR2 4416/4885CASP3 1995/4885MDM4 1846/4885 |
| US-11760723-B2 | Method of preparing a DON prodrug from L-pyroglutamic acid | GLS, GLS2, GLO1 | TLR2 4442/4885CASP3 678/4885MDM4 1631/4885 |
| US-20220194898-A1 | METHOD OF PREPARING A DON PRODRUG FROM L-PYROGLUTAMIC ACID | GLS, GLS2, GLO1 | TLR2 4442/4885CASP3 678/4885MDM4 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.